A method of drug infusion based on blood glucose monitoring and related devices

Abstract

The application relates to the technical field of blood glucose concentration detection, in particular to a medicine injection method based on blood glucose monitoring and related devices. The method comprises the following steps: determining the label type of a target patient, determining a monitoring mode according to the label type; receiving a blood glucose concentration value of the target patient; acquiring a body weight value of the target patient, determining a medicine injection type and a medicine infusion rate for the target patient according to the body weight value and the blood glucose concentration value of the target patient; and controlling an intelligent micro pump to perform medicine infusion of the medicine injection type on the target patient at the medicine infusion rate. Through the closed loop of "real-time monitoring-intelligent analysis-automatic feedback", the application can effectively prevent the occurrence of serious hyperglycemia or hypoglycemia events, and improve the treatment quality of critical patients.

Description

Technical Field

[0001] This application relates to the field of blood glucose concentration detection technology, and in particular to a drug injection method and related device based on blood glucose monitoring. Background Technology

[0002] In the Intensive Care Unit (ICU), monitoring and regulating the vital signs of critically ill patients is central to their treatment. Blood glucose and blood pressure monitoring are crucial methods; however, existing methods lead to the following problems: 1. Independent and invasive repetitive monitoring methods: Ambulatory blood pressure monitoring typically achieves continuous and accurate blood pressure measurement through an indwelling arterial catheter. Blood glucose monitoring, on the other hand, generally involves repeated finger pricks, requiring multiple daily pricks. This independent monitoring method not only increases the workload for medical staff but also inflicts pain and infection risks on patients due to repeated punctures. 2. Isolated blood glucose data, unable to be integrated with real-time control: Traditional bedside blood glucose meters provide isolated data. While some continuous glucose monitoring systems (CGMS) offer continuous data, this data is usually displayed on separate devices, failing to achieve synchronous integration, comparison, and analysis with the patient's core vital signs data on the same platform. 3. Delayed and manual blood glucose control: Currently, insulin or high-glucose infusions largely rely on manual assessment and adjustment of microinfusion pump parameters by medical staff after intermittent blood glucose measurements. This method has a slow response time and cannot achieve precise control at the minute level. When the patient's condition changes drastically, it can easily lead to excessively high or low blood sugar, increasing medical risks. Summary of the Invention

[0003] To address the aforementioned problems, this application provides a drug injection method and related apparatus based on blood glucose monitoring, which can solve at least one of the above-mentioned technical problems.

[0004] According to one aspect of the embodiments of this application, a drug infusion method based on blood glucose monitoring is proposed, applied in an integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system. The integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system includes a blood pressure monitoring module for connecting to a patient's arterial catheter, a blood glucose monitoring module for detecting the patient's blood glucose concentration, and an intelligent micro-pump for infusing insulin or a high-glucose solution into the patient. The blood glucose monitoring module is connected to the blood pressure monitoring module. The method includes: Determine the label type of the target patient, and determine the monitoring method for the target patient based on the label type; During the monitoring of the target patient according to the monitoring method, the blood glucose concentration value of the target patient is received by the blood glucose monitoring module; Obtain the weight value of the target patient, and determine the drug injection type and the corresponding drug infusion rate for the target patient based on the weight value and the blood glucose concentration value of the target patient; The intelligent micro-pump is controlled to deliver the drug of the specified type to the target patient at the specified drug infusion rate; The drug injection type is insulin or a high-glucose solution.

[0005] In the above scheme, determining the monitoring method for the target patient based on the target patient's label type includes: If the target patient's label type is postoperative monitoring, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value every 6 hours; If the target patient's label type is a non-diabetic basic severe patient label, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value once every 2 hours for 2 days; If the target patient's label type is a patient with severe underlying diabetes, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value every 2 hours; If the target patient's label type is hypoglycemia, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value once every 15 minutes; If the target patient's label type is an insulin dose change label, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value once every 1 hour.

[0006] In the above scheme, determining the drug injection type and corresponding drug infusion rate for the target patient based on the target patient's weight and blood glucose concentration includes: If the blood glucose concentration of the target patient is greater than the preset baseline blood glucose threshold and less than or equal to the first preset blood glucose concentration, then the drug injection type is determined to be insulin, and the drug infusion rate is determined to be the body weight multiplied by the first preset coefficient. If the blood glucose concentration of the target patient is greater than the first preset blood glucose concentration, then the drug injection type is determined to be insulin, and the drug infusion rate is determined to be the body weight multiplied by the second preset coefficient. The second preset coefficient is twice the first preset coefficient.

[0007] In the above scheme, determining the drug injection type and corresponding drug infusion rate for the target patient based on the target patient's weight and blood glucose concentration further includes: If the blood glucose concentration of the target patient is less than the preset baseline blood glucose threshold and less than or equal to the second preset blood glucose concentration, then the drug injection type is determined to be a high glucose solution, and the drug infusion rate is determined to be an intravenous injection of 15 to 20 grams of glucose into the target patient within a preset infusion time. If the blood glucose concentration of the target patient is less than the third preset blood glucose concentration, then the drug infusion rate is determined to be an intravenous injection of 25g of glucose into the target patient. Specifically, after intravenously injecting 15 to 20 grams of glucose or 25 grams of glucose into the target patient, the blood glucose concentration value of the target patient is obtained at preset intervals.

[0008] In the above scheme, the method further includes: In the process of controlling the intelligent micro-pump to administer the drug of the drug injection type to the target patient at the drug infusion rate, the infusion dose to the target patient is determined based on the target patient's weight and the drug infusion rate; If the target patient is eating, the infusion dose is doubled.

[0009] In the above scheme, the method further includes: If, during insulin infusion for the target patient, the target patient has not eaten for more than 2 hours and the target patient's blood glucose concentration is below the preset baseline blood glucose threshold, the intelligent micro-pump will be controlled to stop infusing insulin into the target patient.

[0010] In the above scheme, the integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system is also used to connect the blood pressure monitoring module of the patient's arterial catheter, and the method further includes: Receives the blood pressure value of the target patient acquired by the blood pressure monitoring module; If the blood pressure value is greater than the first preset blood pressure threshold, a high blood pressure warning message is sent to the terminal device. If the blood pressure value is less than the second preset blood pressure threshold, a low blood pressure warning message is sent to the terminal device. The first preset blood pressure threshold is greater than the second preset blood pressure threshold.

[0011] According to one aspect of the embodiments of this application, a drug infusion device based on blood glucose monitoring is proposed, which is applied in an integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system. The integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system includes a blood pressure monitoring module for connecting to a patient's arterial catheter, a blood glucose monitoring module for detecting the patient's blood glucose concentration, and an intelligent micro-pump for infusing insulin or a high-glucose solution into the patient. The blood glucose monitoring module is connected to the blood pressure monitoring module. The device includes: A determining unit is used to determine the label type of a target patient and, based on the label type of the target patient, determine the monitoring method for the target patient. The receiving unit is used to receive the blood glucose concentration value of the target patient collected by the blood glucose monitoring module during the monitoring of the target patient according to the monitoring method. The acquisition unit is used to acquire the weight value of the target patient, and determine the drug injection type and the corresponding drug infusion rate for the target patient based on the weight value and the blood glucose concentration value of the target patient; A control unit is used to control the intelligent micro-pump to administer the drug infusion type to the target patient at the drug infusion rate; The drug injection type is insulin or a high-glucose solution. According to one aspect of the embodiments of this application, a computer program product is provided, the computer program product including a computer program that is read and executed by a processor of an electronic device, causing the electronic device to perform the blood glucose monitoring-based drug injection method as described above.

[0012] The beneficial effects of this application are as follows: By placing the blood glucose monitoring module into the patient's arterial catheter, this application completely avoids the need for repeated finger-prick or venous blood sampling for blood glucose testing, greatly reducing the patient's pain and trauma, and lowering the risk of local and bloodstream infections.

[0013] This application provides different monitoring methods for target patients with different label types. During the monitoring process, the type of medication and the corresponding infusion rate are determined based on the target patient's weight and the measured blood glucose concentration. This dynamically adjusts the medication type and infusion efficiency for target patients with different label types, establishing a closed loop of "real-time monitoring - intelligent analysis - automatic feedback." This upgrades blood glucose management from "intermittent measurement and manual adjustment" to "continuous monitoring and automatic control," effectively preventing severe hyperglycemia or hypoglycemia events and improving the quality of care for critically ill patients. This application also reduces the repetitive work of medical staff in frequently measuring blood glucose, calculating dosages, and adjusting pump rates, thus lowering labor costs. Attached Figure Description

[0014] Figure 1 This is a system architecture diagram of the drug injection method based on blood glucose monitoring provided in the embodiments of this application; Figure 2 A schematic flowchart of a drug injection method based on blood glucose monitoring provided in an embodiment of this application; Figure 3 This is an architecture diagram of the integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system provided in the embodiments of this application; Figure 4 This is a schematic diagram of the closed-loop blood glucose control provided in the embodiments of this application; Figure 5 A block diagram of a drug injection device based on blood glucose monitoring provided in an embodiment of this application; Figure 6 This is a schematic diagram of the structure of a terminal provided in an embodiment of this application; Figure 7 This is a schematic diagram of the structure of a server provided in an embodiment of this application. Detailed Implementation

[0015] To enable those skilled in the art to better understand the solutions of this application, the technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0016] It should be noted that while some processes described in the specification, claims, and accompanying drawings include multiple steps appearing in a specific order, it should be clearly understood that these steps may not be performed in the order they appear herein, or may be performed in parallel. The step numbers are merely used to distinguish different steps and do not themselves represent any execution order. Furthermore, descriptions such as "first," "second," or "objective" in this document are used to distinguish similar objects and are not necessarily used to describe a specific order or sequence. "Multiple" in this document refers to at least two.

[0017] It is worth noting that in the specific embodiments of this application, data such as blood glucose concentration and blood pressure are involved. When the above embodiments of this application are applied to specific products or technologies, permission or consent from the target object is required, and the collection, use, and processing of related data must comply with relevant laws, regulations, and standards. For example, when an embodiment of this application needs to obtain data such as blood glucose concentration and blood pressure, separate permission or consent from the target object can be obtained through pop-up windows or redirection to a confirmation page. After obtaining the separate permission or consent from the target object, the relevant data such as blood glucose concentration and blood pressure used to enable the embodiment of this application to operate normally can then be obtained.

[0018] Please see Figure 1 , Figure 1 This is a system architecture diagram of the drug injection method based on blood glucose monitoring provided in the embodiments of this application. It includes a terminal 140, an Internet connection 130, a gateway 120, a server 110, etc.

[0019] Terminal 140 can take various forms, including desktop computers, laptops, PDAs (personal digital assistants), mobile phones, vehicle terminals, and dedicated terminals. Furthermore, it can be a single device or a collection of multiple devices. For example, multiple desktop computers can be interconnected via a local area network, sharing a single monitor to work collaboratively, forming a single terminal 140. Terminal 140 can communicate with the Internet 130 via wired or wireless means to exchange data.

[0020] Server 110 refers to a computer system capable of providing certain services to terminal 140. Compared to ordinary terminal 140, server 110 has higher requirements in terms of stability, security, and performance. Server 110 can be a single high-performance computer in a network platform, a cluster of multiple high-performance computers, a portion of a single high-performance computer (e.g., a virtual machine), or a combination of portions of multiple high-performance computers (e.g., virtual machines). Server 110 can also communicate with the Internet 130 via wired or wireless means to exchange data.

[0021] Gateway 120, also known as an internetwork connector or protocol converter, is a computer system or device that acts as a translator, enabling network interconnection at the transport layer. It bridges the gap between two systems using different communication protocols, data formats, languages, or even completely different architectures. Gateways can also provide filtering and security functions. Messages sent from terminal 140 to server 110 are forwarded to the corresponding server 110 via gateway 120. Messages sent from server 110 to terminal 140 are also forwarded to the corresponding terminal 140 via gateway 120.

[0022] The following provides a detailed description of the specific implementation methods of the embodiments of this application: Please see Figure 2 , Figure 2 This is a schematic flowchart of a drug injection method based on blood glucose monitoring provided in an embodiment of this application. The drug injection method based on blood glucose monitoring can be implemented by server 110 and / or terminal 140. Figure 2 The illustrated drug infusion method based on blood glucose monitoring includes: Step 210: Determine the label type of the target patient, and determine the monitoring method for the target patient based on the label type; Step 220: During the monitoring of the target patient according to the monitoring method, receive the blood glucose concentration value of the target patient collected by the blood glucose monitoring module; Step 230: Obtain the weight value of the target patient, and determine the drug injection type and the corresponding drug infusion rate for the target patient based on the weight value and the blood glucose concentration value of the target patient; Step 240: Control the intelligent micro-pump to administer the drug of the drug injection type to the target patient at the drug infusion rate.

[0023] First, the integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system of this application can be combined with Figure 3 As shown, it includes a patient-side module for a dynamic blood pressure monitor (blood pressure monitoring module), an integrated blood glucose sensor module (blood glucose monitoring module), a multi-parameter monitor, and a smart micro-infusion pump.

[0024] The patient-side module of the ambulatory blood pressure monitor (i.e., the blood pressure monitoring module described in this application) is used to connect to the patient's arterial catheter and includes a pressure sensor for continuously acquiring arterial blood pressure signals.

[0025] An integrated blood glucose sensing module (i.e., the blood glucose monitoring module described in this application) has an electrochemical enzyme sensing electrode at its core. This module is aseptically and connectably integrated into the blood flow path of the patient-side module of the ambulatory blood pressure monitor (e.g., connected between the arterial pressure transducer and the arterial catheter via a three-way valve). When the patient's blood flows through this module, the enzyme sensing electrode continuously detects the glucose concentration in the blood through an electrochemical reaction and generates a corresponding electrical signal.

[0026] Multi-parameter monitor: Receives blood pressure signals from the blood pressure monitoring module and blood glucose signals from the blood glucose monitoring module via cables. The multi-parameter monitor has a built-in or external signal processing unit to amplify, filter, and calculate the signals, displaying the patient's continuous arterial blood pressure curve and continuous blood glucose concentration curve in real-time and synchronously on the same display interface, in both digital and waveform formats. The measured blood glucose concentration can be displayed on the multi-parameter monitor, the insulin pump rate can be manually adjusted, and the pump rate of the intelligent micro-infusion pump can be adjusted both adaptively and manually.

[0027] Intelligent micro-infusion pump: Connected to the multi-parameter monitor via a wired or wireless communication module. The monitor transmits processed real-time blood glucose data to the intelligent micro-infusion pump.

[0028] Closed-loop control unit (the core of this application): This unit can be integrated into a smart micro-infusion pump or monitor. It has a preset target blood glucose range (a concentration range characterizing the normal blood glucose range in the human body), i.e., a preset baseline blood glucose threshold, which can be any value between 8 mg / dL and 10 mg / dL. The closed-loop control unit receives blood glucose data in real time, automatically compares and calculates it with the target value (i.e., the preset baseline blood glucose threshold), and adjusts the infusion rate of the smart micro-infusion pump in real time and automatically—when blood glucose is higher than the preset baseline blood glucose threshold, it controls the pumping of insulin; when blood glucose is lower than the preset baseline blood glucose threshold, it controls the pumping of a high-glucose solution, thereby achieving fully automatic closed-loop precise management of blood glucose levels.

[0029] A specific flowchart can be shown as follows: Figure 4 As shown, S1: System initialization, setting the target blood glucose range.

[0030] S2: Integrated sensor continuously monitors real-time blood glucose concentration.

[0031] S3: The closed-loop control unit reads the real-time blood glucose concentration value.

[0032] S4: Compare the real-time blood glucose concentration value with the target range, that is, compare the blood glucose concentration value described in this application with the preset benchmark blood glucose threshold.

[0033] S5: Determine whether the blood glucose concentration is within the target range (i.e., whether the blood glucose concentration value described in this application is within the preset baseline blood glucose threshold range of 8 mg / dL-10 mg / dL)? If “Yes”: Return to step S2 and continue monitoring.

[0034] If “No”: Proceed to step S6.

[0035] S6: Calculate the required insulin or high-glucose solution infusion rate; S7: Send a command to the intelligent micro-pump to adjust the infusion rate.

[0036] S8: Micro-infusion pump performs infusion.

[0037] In some embodiments, determining the monitoring method for the target patient based on the target patient's label type includes: If the target patient's label type is postoperative monitoring, then the monitoring method for the target patient is determined to be obtaining the target patient's blood glucose concentration and blood pressure values ​​every 6 hours. Here, the clinician can also decide whether to continue monitoring based on the actual situation. If the target patient's label type is a non-diabetic, severely ill patient label, then the monitoring method for the target patient is determined to be obtaining the target patient's blood glucose concentration and blood pressure values ​​every 2 hours for 2 days. Here, the clinician can also decide whether to continue monitoring based on the actual situation.

[0038] If the target patient's label type is a patient with severe underlying diabetes, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value every 2 hours; If the target patient's label type is hypoglycemia, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value once every 15 minutes; If the target patient's label type is an insulin dose change label, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value once every 1 hour.

[0039] Specifically, the time intervals for measuring blood glucose can be freely set. The label for postoperative monitoring is used to identify the target patient as a postoperative monitoring patient. The label for non-diabetic critical patients is used to identify the target patient as a critical patient without underlying diabetes. The label for diabetic critical patients is used to identify the target patient as a critical patient with underlying diabetes. The label for hypoglycemia is used to identify the target patient as currently in a hypoglycemic state. The label for insulin dose change is used to identify the target patient as a diabetic patient, and the insulin dose infusion for the target patient is constantly being adjusted.

[0040] In some embodiments, determining the drug injection type and corresponding drug infusion rate for the target patient based on the target patient's weight and blood glucose concentration includes: If the blood glucose concentration of the target patient is greater than the preset baseline blood glucose threshold and less than or equal to the first preset blood glucose concentration, then the drug injection type is determined to be insulin, and the drug infusion rate is determined to be the body weight multiplied by the first preset coefficient. If the blood glucose concentration of the target patient is greater than the first preset blood glucose concentration, then the drug injection type is determined to be insulin, and the drug infusion rate is determined to be the body weight multiplied by the second preset coefficient. The second preset coefficient is twice the first preset coefficient.

[0041] Specifically, the first preset coefficient is, for example, 0.05, and the second preset coefficient is, for example, 0.1, as shown in the example below:

[0042] example: The patient weighs 50 kg, and their blood glucose level is monitored at 12 mmol / L. The initiation or maintenance insulin dose is 50 kg x 0.05 u / kg / h (this represents 0.05 units of medication per kilogram of body weight per hour, multiplied by 50 kg to obtain the infusion rate) = 2.5 U / h. The patient weighs 50 kg, and their blood glucose level is 16 mmol / L. The starting or maintenance insulin dose is 50 kg x 0.1 u / kg / h = 5 u / h. The patient weighs 50 kg and has a blood glucose level of 12 mmol / L. The insulin infusion dose is initiated or maintained at 50 kg x 0.05 U / kg / h + 50 kg x 0.05 U / kg / h = 5 U / h (that is, if the target patient is eating, the infusion dose is doubled).

[0043] In some embodiments, determining the drug injection type and the corresponding drug infusion rate for the target patient based on the target patient's weight and blood glucose concentration further includes: If the blood glucose concentration of the target patient is less than the preset baseline blood glucose threshold and less than or equal to the second preset blood glucose concentration, then the drug injection type is determined to be a high glucose solution, and the drug infusion rate is determined to be an intravenous injection of 15 to 20 grams of glucose into the target patient within a preset infusion time. If the blood glucose concentration of the target patient is less than the third preset blood glucose concentration, then the drug infusion rate is determined to be an intravenous injection of 25g of glucose into the target patient. Specifically, after intravenously injecting 15 to 20 grams of glucose or 25 grams of glucose into the target patient, the blood glucose concentration value of the target patient is obtained at preset intervals.

[0044] Specifically, the preset interval is, for example, 15 minutes; the second preset blood glucose concentration is 3.9 mmol / L; and the third preset blood glucose concentration is 2.8 mmol / L. For target patients with severe hypoglycemia, interrupting insulin infusion is only the first step. However, simply interrupting insulin infusion is not enough; additional intravenous glucose infusion therapy (a high-glucose solution, i.e., glucose) is usually required. Simultaneously, iatrogenic hyperglycemia should be avoided. For example, the dosage of a 50% glucose solution (g) = [100 - blood glucose concentration (mg / dL)] × 0.2g. In hypoglycemic patients receiving intravenous insulin, 10-20g of glucose can raise blood glucose to 4.4-6.1 mmol / L within 30 minutes. Therefore, this application recommends intravenous injection of 15g-20g of glucose to alleviate the low blood glucose level in target patients.

[0045] For critically ill patients who have already developed hypoglycemia, blood glucose should be monitored at least every 15 minutes after glucose therapy, and this should be repeated until blood glucose stabilizes within the target range. When blood glucose is <2.8 mmol / L (third preset blood glucose concentration value): administer 25g of 50% glucose intravenously; retest blood glucose after 15 minutes; When blood glucose is between 2.8 and 4.1 mmol / L, if there are other underlying medical conditions (or symptoms that cannot be assessed), administer 25g of 50% glucose intravenously; retest blood glucose after 15 minutes. If there are no other underlying medical conditions, administer 12.5g of 50% glucose intravenously; retest blood glucose after 15-30 minutes. If the blood glucose level is in the range of 4.4-10 mmol / L, continue to monitor it. If the blood glucose level is >10 mmol / L, inject insulin according to the above logic.

[0046] In some embodiments, the method further includes: If, during insulin infusion for the target patient, the target patient has not eaten for more than 2 hours and the blood glucose concentration is below the preset baseline blood glucose threshold, the intelligent micro-pump will be controlled to stop infusing insulin into the target patient. If the target patient has not eaten for more than 2 hours and the blood glucose concentration is above the preset baseline blood glucose threshold during the infusion of high glucose solution to the target patient, the intelligent micro-pump will be controlled to stop the infusion of high glucose solution to the target patient.

[0047] Specifically, if the patient has not eaten for more than 2 hours, the diet should be stopped once the target value (preset baseline blood glucose threshold) is reached. Alternatively, if the blood glucose level is ≤3.9mmol / L, immediately stop the insulin pump and administer food or 20-40ml of 50% glucose solution intravenously, depending on the situation.

[0048] Special cases: Patients with diabetic ketoacidosis need to receive continuous ketosis infusion while receiving insulin. CRRT is not permitted for patients with hyperkalemia; instead, continuous insulin and glucose infusion is required to lower potassium levels.

[0049] In some embodiments, the method further includes: Receives the blood pressure value of the target patient acquired by the blood pressure monitoring module; If the blood pressure value is greater than the first preset blood pressure threshold, a high blood pressure warning message is sent to the terminal device. If the blood pressure value is less than the second preset blood pressure threshold, a low blood pressure warning message is sent to the terminal device. The first preset blood pressure threshold is greater than the second preset blood pressure threshold.

[0050] Specifically, the first preset blood pressure threshold is 140 mmHg, and the second preset blood pressure threshold is 60 mmHg.

[0051] In some embodiments, the method further includes: Adjusting the insulin infusion rate of the intelligent micro-pump to the patient based on the received blood pressure value includes: If the received blood pressure value is greater than the maximum value of the preset blood pressure value range, the current infusion rate of insulin infusion from the intelligent micro-pump to the patient will be reduced to two-thirds of the current infusion rate. If the received blood pressure value is less than the minimum value of the preset blood pressure range, the current infusion rate of insulin infusion from the intelligent micro-pump to the patient will be increased to five-quarters of the current infusion rate.

[0052] Here, the patient's blood pressure can be continuously monitored during insulin infusion, and the infusion rate can be flexibly adjusted to keep the patient's blood pressure within the preset range.

[0053] In some embodiments, during the process of the intelligent micro-pump infusing insulin into the patient, the blood glucose concentration collected by the blood glucose monitoring module is continuously received; If the third difference between the blood glucose concentration and the preset baseline blood glucose threshold is less than the preset baseline difference, the infusion rate of insulin delivered to the patient by the intelligent micro-pump will be reduced to half of the original rate.

[0054] Here, the third difference is used to characterize the difference between the blood glucose concentration and the preset baseline blood glucose threshold during the process of the intelligent micro-infusion pump infusing insulin into the patient. The preset baseline difference is used to determine whether the patient's blood glucose concentration is close to the normal range, that is, whether it is close to the preset baseline blood glucose threshold. If it is less than the baseline difference, it means that the patient's blood glucose concentration is close to the normal range. At this time, the infusion rate can be adjusted, and the first remaining infusion time can be determined accordingly. Finally, the intelligent micro-infusion pump is controlled to infuse insulin into the patient at the first remaining infusion time and the reduced infusion rate (that is, half of the current infusion rate). After the first remaining infusion time is reached, the intelligent micro-infusion pump is controlled to stop infusing insulin into the patient.

[0055] In summary, this application, by placing the blood glucose monitoring module into the patient's arterial catheter, completely avoids repeated finger-prick or venous blood sampling for blood glucose testing, greatly reducing patient pain and trauma, and lowering the risk of local and bloodstream infections. By establishing a closed loop of "real-time monitoring - intelligent analysis - automatic feedback," blood glucose management is upgraded from "intermittent measurement and manual adjustment" to "continuous monitoring and automatic control," significantly improving the maintenance rate of blood glucose within the target range (fluctuating around a preset baseline blood glucose threshold), effectively preventing severe hyperglycemia or hypoglycemia events, and improving the quality of treatment for critically ill patients. This application also reduces the repetitive work of medical staff in frequently measuring blood glucose, calculating dosages, and adjusting pump rates, which can reduce labor costs and largely avoid problems caused by operational errors of nursing staff.

[0056] Please see Figure 5 , Figure 5 This is a schematic diagram of a blood glucose monitoring-based drug injection device provided in an embodiment of this application. The blood glucose monitoring-based drug injection device is applied to a computer device, and may include: The determining unit 401 is used to determine the label type of the target patient and determine the monitoring method for the target patient based on the label type of the target patient. The receiving unit 402 is used to receive the blood glucose concentration value of the target patient collected by the blood glucose monitoring module during the process of monitoring the target patient according to the monitoring method. The acquisition unit 403 is used to acquire the weight value of the target patient, and determine the drug injection type and the drug infusion rate corresponding to the drug injection type based on the weight value and the blood glucose concentration value of the target patient. Control unit 404 is used to control the intelligent micro-pump to administer the drug of the drug injection type to the target patient at the drug infusion rate.

[0057] Reference Figure 6 , Figure 6 To implement the structural block diagram of a portion of the terminal 140 in this application embodiment, the terminal 140 includes: a radio frequency (RF) circuit 710, a memory 715, an input unit 730, a display unit 740, a sensor 750, an audio circuit 760, a wireless fidelity (WiFi) module 770, a processor 780, and a power supply 790, among other components. Those skilled in the art will understand that... Figure 6 The terminal 140 structure shown does not constitute a limitation on a mobile phone or computer, and may include more or fewer components than shown, or combine certain components, or have different component arrangements.

[0058] The RF circuit 710 can be used to receive and transmit signals during information transmission or calls. In particular, it receives downlink information from the base station and processes it with the processor 780; in addition, it transmits uplink data to the base station.

[0059] The memory 715 can be used to store software programs and modules. The processor 780 executes various functional applications of the terminal and drug injection processing based on blood glucose monitoring by running the software programs and modules stored in the memory 715.

[0060] The input unit 730 can be used to receive input numeric or character information, and to generate key signal inputs related to the terminal's settings and function control. Specifically, the input unit 730 may include a touch panel 731 and other input devices 732.

[0061] The display unit 740 can be used to display input or provided information, as well as various menus of the terminal. The display unit 740 may include a display panel 741.

[0062] Audio circuitry 760, speaker 761, and microphone 762 provide an audio interface.

[0063] In this embodiment, the processor 780 included in the terminal 140 can execute the blood glucose monitoring-based drug injection method of the previous embodiment.

[0064] The terminal 140 in this application embodiment includes, but is not limited to, mobile phones, computers, intelligent voice interaction devices, smart home appliances, vehicle terminals, and aircraft. This application embodiment can be applied to various scenarios, including but not limited to cloud technology, artificial intelligence, smart transportation, and assisted driving.

[0065] Figure 7 This is a partial structural block diagram of a server 110 implementing an embodiment of this application. The server 110 can vary significantly due to different configurations or performance characteristics, and may include one or more central processing units (CPUs) 822 (e.g., one or more processors) and memory 832, and one or more storage media 830 (e.g., one or more mass storage devices) for storing application programs 842 or data 844. The memory 832 and storage media 830 can be temporary or persistent storage. The program stored in the storage media 830 may include one or more modules (not shown in the diagram), each module including a series of instruction operations on the server 110. Furthermore, the CPU 822 may be configured to communicate with the storage media 830 and execute the series of instruction operations in the storage media 830 on the server 110.

[0066] Server 110 may also include one or more power supplies 826, one or more wired or wireless network interfaces 850, one or more input / output interfaces 858, and / or one or more operating systems 841, such as Windows Server™, Mac OS X™, Unix™, Linux™, FreeBSD™, etc.

[0067] The central processing unit 822 in server 110 can be used to execute the blood glucose monitoring-based drug injection method of this application embodiment.

[0068] This application also provides a computer-readable storage medium for storing program code for executing the blood glucose monitoring-based drug injection method of the foregoing embodiments.

[0069] This application also provides a computer program product, which includes a computer program. The processor of a computer device reads and executes the computer program, causing the computer device to perform the above-described drug injection method based on blood glucose monitoring.

[0070] Furthermore, the terms “comprising” and “including”, and any variations thereof, are intended to cover non-exclusive inclusion, such that a process, method, system, product, or apparatus that includes a series of steps or units is not necessarily limited to those steps or units that are explicitly listed, but may include other steps or units that are not explicitly listed or that are inherent to such process, method, product, or apparatus.

[0071] It should be understood that in this application, "at least one (item)" means one or more, and "more than" means two or more. "And / or" is used to describe the relationship between related objects, indicating that three relationships can exist. For example, "A and / or B" can represent three cases: only A exists, only B exists, and both A and B exist simultaneously, where A and B can be singular or plural. The character " / " generally indicates that the preceding and following related objects are in an "or" relationship. "At least one (item) of the following" or similar expressions refer to any combination of these items, including any combination of single or plural items. For example, at least one (item) of a, b, or c can represent: a, b, c, "a and b", "a and c", "b and c", or "a and b and c", where a, b, and c can be single or multiple.

[0072] It should be understood that in the description of the embodiments of this application, "multiple" means two or more, "greater than", "less than", "exceeding" etc. are understood to exclude the number itself, and "above", "below", "within" etc. are understood to include the number itself.

[0073] In the several embodiments provided in this application, it should be understood that the disclosed systems, apparatuses, and methods can be implemented in other ways. For example, the apparatus embodiments described above are merely illustrative; for instance, the division of units is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple units or components may be combined or integrated into another system, or some features may be ignored or not executed. Furthermore, the coupling or direct coupling or communication connection shown or discussed may be through some interfaces, or indirect coupling or communication connection between apparatuses or units, and may be electrical, mechanical, or other forms.

[0074] The units described as separate components may or may not be physically separate. The components shown as units may or may not be physical units; that is, they may be located in one place or distributed across multiple network units. Some or all of the units can be selected to achieve the purpose of the embodiments of this application, depending on actual needs.

[0075] Furthermore, the functional units in the various embodiments of this application can be integrated into one processing unit, or each unit can exist physically separately, or two or more units can be integrated into one unit. The integrated unit can be implemented in hardware or as a software functional unit.

[0076] If the integrated unit is implemented as a software functional unit and sold or used as an independent product, it can be stored in a computer-readable storage medium. Based on this understanding, the technical solution of this application, in essence, or the part that contributes to the prior art, or all or part of the technical solution, can be embodied in the form of a software product. This computer software product is stored in a storage medium and includes several instructions to cause a computer device (which may be a personal computer, server, or network device, etc.) to execute all or part of the steps of the methods of the various embodiments of this application. The aforementioned storage medium includes various media capable of storing program code, such as USB flash drives, portable hard drives, read-only memory (ROM), random access memory (RAM), magnetic disks, or optical disks.

[0077] It should also be understood that the various implementation methods provided in this application can be combined arbitrarily to achieve different technical effects.

[0078] In the embodiments of this application, the terms "module" or "unit" refer to a computer program or part of a computer program that has a predetermined function and works with other related parts to achieve a predetermined goal, and can be implemented wholly or partially using software, hardware (such as processing circuitry or memory), or a combination thereof. Similarly, a processor (or multiple processors or memory) can be used to implement one or more modules or units. Furthermore, each module or unit can be part of an overall module or unit that includes the functionality of that module or unit.

[0079] The above is a detailed description of the embodiments of this application. However, this application is not limited to the above embodiments. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of this application. All such equivalent modifications or substitutions are included within the scope defined by the claims of this application.

Claims

1. A drug injection method based on blood glucose monitoring, characterized in that, An integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system is applied to this system. The integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system includes a blood pressure monitoring module for connecting to a patient's arterial catheter, a blood glucose monitoring module for detecting the patient's blood glucose concentration, and a smart micro-pump for infusing insulin or a high-glucose solution into the patient. The blood glucose monitoring module is connected to the blood pressure monitoring module. The method includes: Determine the label type of the target patient, and determine the monitoring method for the target patient based on the label type; During the monitoring of the target patient according to the monitoring method, the blood glucose concentration value of the target patient is received by the blood glucose monitoring module; Obtain the weight value of the target patient, and determine the drug injection type and the corresponding drug infusion rate for the target patient based on the weight value and the blood glucose concentration value of the target patient; The intelligent micro-pump is controlled to deliver the drug of the specified type to the target patient at the specified drug infusion rate; The drug injection type is insulin or a high-glucose solution.

2. The drug injection method based on blood glucose monitoring according to claim 1, characterized in that, The step of determining the monitoring method for the target patient based on the target patient's label type includes: If the target patient's label type is postoperative monitoring, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value every 6 hours; If the target patient's label type is a non-diabetic basic severe patient label, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value once every 2 hours for 2 days; If the target patient's label type is a patient with severe underlying diabetes, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value and blood pressure value every 2 hours; If the target patient's label type is hypoglycemia, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value once every 15 minutes; If the target patient's label type is an insulin dose change label, then the monitoring method for the target patient is determined to be to obtain the target patient's blood glucose concentration value once every 1 hour.

3. The drug injection method based on blood glucose monitoring according to claim 1, characterized in that, The step of determining the drug injection type and corresponding drug infusion rate for the target patient based on the target patient's weight and blood glucose concentration includes: If the blood glucose concentration of the target patient is greater than the preset baseline blood glucose threshold and less than or equal to the first preset blood glucose concentration, then the drug injection type is determined to be insulin, and the drug infusion rate is determined to be the body weight multiplied by the first preset coefficient. If the blood glucose concentration of the target patient is greater than the first preset blood glucose concentration, then the drug injection type is determined to be insulin, and the drug infusion rate is determined to be the body weight multiplied by the second preset coefficient. The second preset coefficient is twice the first preset coefficient.

4. The drug injection method based on blood glucose monitoring according to claim 3, characterized in that, The step of determining the drug injection type and corresponding drug infusion rate for the target patient based on the target patient's weight and blood glucose concentration also includes: If the blood glucose concentration of the target patient is less than the preset baseline blood glucose threshold and less than or equal to the second preset blood glucose concentration, then the drug injection type is determined to be a high glucose solution, and the drug infusion rate is determined to be an intravenous injection of 15 to 20 grams of glucose into the target patient within a preset infusion time. If the blood glucose concentration of the target patient is less than the third preset blood glucose concentration, then the drug infusion rate is determined to be an intravenous injection of 25g of glucose into the target patient. Specifically, after intravenously injecting 15 to 20 grams of glucose or 25 grams of glucose into the target patient, the blood glucose concentration value of the target patient is obtained at preset intervals.

5. The drug injection method based on blood glucose monitoring according to claim 4, characterized in that, The method further includes: In the process of controlling the intelligent micro-pump to administer the drug of the drug injection type to the target patient at the drug infusion rate, the infusion dose to the target patient is determined based on the target patient's weight and the drug infusion rate; If the target patient is eating, the infusion dose is doubled.

6. The drug injection method based on blood glucose monitoring according to claim 5, characterized in that, The method further includes: If, during insulin infusion for the target patient, the target patient has not eaten for more than 2 hours and the target patient's blood glucose concentration is below the preset baseline blood glucose threshold, the intelligent micro-pump will be controlled to stop infusing insulin into the target patient.

7. The drug injection method based on blood glucose monitoring according to claim 1, characterized in that, The integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system is also used to connect a blood pressure monitoring module to the patient's arterial catheter, and the method further includes: Receives the blood pressure value of the target patient acquired by the blood pressure monitoring module; If the blood pressure value is greater than the first preset blood pressure threshold, a high blood pressure warning message is sent to the terminal device. If the blood pressure value is less than the second preset blood pressure threshold, a low blood pressure warning message is sent to the terminal device. The first preset blood pressure threshold is greater than the second preset blood pressure threshold.

8. A drug infusion device based on blood glucose monitoring, characterized in that, An integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system is applied in the device. The integrated dynamic blood glucose and blood pressure monitoring and closed-loop control system includes a blood pressure monitoring module for connecting to a patient's arterial catheter, a blood glucose monitoring module for detecting the patient's blood glucose concentration, and a smart micro-pump for infusing insulin or a high-glucose solution into the patient. The blood glucose monitoring module is connected to the blood pressure monitoring module. The device includes: A determining unit is used to determine the label type of a target patient and, based on the label type of the target patient, determine the monitoring method for the target patient. The receiving unit is used to receive the blood glucose concentration value of the target patient collected by the blood glucose monitoring module during the monitoring of the target patient according to the monitoring method. The acquisition unit is used to acquire the weight value of the target patient, and determine the drug injection type and the corresponding drug infusion rate for the target patient based on the weight value and the blood glucose concentration value of the target patient; A control unit is used to control the intelligent micro-pump to administer the drug infusion type to the target patient at the drug infusion rate; The drug injection type is insulin or a high-glucose solution.

9. An electronic device comprising a memory and a processor, wherein the memory stores a computer program, characterized in that, When the processor executes the computer program, it implements the drug injection method based on blood glucose monitoring as described in any one of claims 1 to 7.

10. A computer program product, the computer program product comprising a computer program, characterized in that, The computer program is read and executed by the processor of the electronic device, causing the electronic device to perform the drug injection method based on blood glucose monitoring as described in any one of claims 1 to 7.

Images